SCHEMBL23886987

SCHEMBL23886987

CCSc1cc(=O)c2cc(Cl)cc(Br)c2o1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SIRT2 Q8IXJ6 2/20 0.56
▸ MAOB P27338 3/20 0.37
▸ MAOA P21397 1/20 0.36
▸ CSNK2A2 P19784 5/20 0.35
▸ CSNK2B P67870 5/20 0.35
▸ CSNK2A1 P68400 5/20 0.35
▸ CDK1 P06493 2/20 0.35
▸ CCNB1 P14635 2/20 0.35
▸ CCNE2 O96020 1/20 0.35
▸ CDK4 P11802 1/20 0.35
▸ CCND1 P24385 1/20 0.35
▸ CCNE1 P24864 1/20 0.35
▸ CDK2 P24941 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ GABRP O00591 3/20 0.34
▸ GABRD O14764 3/20 0.34
▸ GABRA1 P14867 3/20 0.34
▸ GABRB1 P18505 3/20 0.34
▸ GABRG2 P18507 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23887012 0.84 CSNK2A2 (0.40) SIRT2MAOBCSNK2A2CSNK2BCSNK2A1
SCHEMBL23887043 0.83 SIRT2 (0.39) SIRT2CSNK2A2CSNK2BCSNK2A1CDK1
SCHEMBL30434136 0.81 SIRT2 (0.38) SIRT2MAOBCSNK2A2CSNK2BCSNK2A1
SCHEMBL23887067 0.80 DDR1 (0.40) SIRT2CSNK2A2CSNK2BCSNK2A1CDK1
SCHEMBL30307533 0.80 DDR1 (0.40) SIRT2CSNK2A2CSNK2BCSNK2A1CDK1
SCHEMBL30564466 0.80 MAOB (0.38) SIRT2MAOBMAOACSNK2A2CSNK2B
SCHEMBL23887366 0.78 LOXL2 (0.54) SIRT2CDK1CCNB1CCNE2CDK4
SCHEMBL24714304 0.74 CCNE2 (0.35) SIRT2CSNK2A2CSNK2BCSNK2A1CDK1
SCHEMBL23887096 0.74 SIRT2 (0.56) SIRT2MAOBMAOACSNK2A2CSNK2B
SCHEMBL30564398 0.73 ELANE (0.35) SIRT2CDK1CCNB1CCNE2CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230286960-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE LOXO ONCOLOGY, INC. 2023-09-14 — — US disclosed
US-11649227-B2 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease PETRA PHARMA CORPORATION (US) 2023-05-16 — — US disclosed
CN-115956075-A Allosteric enone inhibitors of phosphoinositide 3-kinases (PI 3 ks) for the treatment of diseases associated with PI3K modulation 佩特拉制药公司 2023-04-11 — — CN disclosed
EP-4126851-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASES ASSOCIATED WITH P13K MODULATION Petra Pharma Corporation (US) 2023-02-08 — — EP disclosed
US-20220372023-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE LOXO ONCOLOGY, INC. 2022-11-24 — — US disclosed
WO-2021202964-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASES ASSOCIATED WITH P13K MODULATION PETRA PHARMA CORPORATION (US) 2021-10-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230286960-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PIK3CA, AKT3, PIK3R1 SIRT2 3697/4885MAOB 2464/4885MAOA 2811/4885
US-20220372023-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PIK3CA, AKT3, PIK3R1 SIRT2 3697/4885MAOB 2464/4885MAOA 2811/4885
US-11649227-B2 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease PIK3CA, AKT3, PIK3R1 SIRT2 3697/4885MAOB 2464/4885MAOA 2811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback